Precigen Inc

NASDAQ:PGENUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Contact Information

Headquarters

20374 SENECA MEADOWS PARKWAYGERMANTOWN, MD, United States 20876

Phone

301-556-9900

Fax

---

Executives

Executive Chairman of the Board

Randal Kirk

President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.

Helen Sabzevari

Chief Financial Officer

Harry Thomasian

Chief Operating Officer

Rutul Shah

Chief Commercial Officer

Phil Tennant